Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Current Assets (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Current Assets for 7 consecutive years, with $871.2 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 70.74% to $871.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $871.2 million through Dec 2025, up 70.74% year-over-year, with the annual reading at $871.2 million for FY2025, 70.74% up from the prior year.
  • Current Assets for Q4 2025 was $871.2 million at Kymera Therapeutics, up from $528.3 million in the prior quarter.
  • The five-year high for Current Assets was $871.2 million in Q4 2025, with the low at $340.8 million in Q1 2021.
  • Average Current Assets over 5 years is $489.8 million, with a median of $472.6 million recorded in 2021.
  • The sharpest move saw Current Assets soared 82.85% in 2021, then fell 23.95% in 2023.
  • Over 5 years, Current Assets stood at $451.3 million in 2021, then decreased by 7.06% to $419.4 million in 2022, then decreased by 3.36% to $405.3 million in 2023, then increased by 25.89% to $510.3 million in 2024, then soared by 70.74% to $871.2 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $871.2 million, $528.3 million, and $728.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.